Pro-survival members of the BCL-2 protein family (e.g., BCL-2, BCL-XL, MCL-1) are well-established targets for the treatment of various cancers as well as diseases outside of oncology. AbbVie generated the first viable small molecule inhibitor of this class of proteins in navitoclax, a dual-targeting asset which engages BCL-2 and BCL-XL with similar affinity. Preclinical and clinical experience with navitoclax spurred the generation of selective inhibitors against several BCL-2 family proteins, and AbbVie now has clinical-stage assets targeting all three primary pro-survival family members. This seminar will describe highlights and challenges along this path to clinical development.

Selective targeting of pro-survival BCL-2 family proteins

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.